Carl Zeiss Meditec Inc.
!%Carl Zeiss Meditec Inc.%! of Dublin, Calif., has announced
that the Mel 80 excimer laser has received premarket approval for the treatment
of hyperopia, or farsightedness, from the FDA. This hyperopia indication complements
existing FDA-approved applications of the surgical laser for myopia and astigmatism,
according to the company. It will allow the company to offer a broader range of
treatment options to refractive surgeons and their patients. The device combines
high-grade optics and advanced laser technology. Clinical results of the Mel 80
study for hyperopia were presented in March at the American Society of Cataract
and Refractive Surgery in San Diego.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024